C-reactive protein and cardiovascular risk: more fuel to the fire

The Lancet

Volumn 375, Issue 9709, 2010, Pages 95-96

  Boekholdt, S Matthijs ^a   Kastelein, John JP ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; PREDICTIVE VALIDITY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RISK ASSESSMENT;

EID: 73449095191     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)62098-5     Document Type: Note

References (14)

1. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
2. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331 (1994) 417-424
3. The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 10.1016/S0140-6736(09)61717-7 published online Dec 22.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
5. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
6. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
7. Cook N.R., Buring J.E., and Ridker P.M. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145 (2006) 21-29
8. Rana J.S., Cote M., Despres J.P., et al. Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk; the EPIC-Norfolk prospective population study. Heart 95 (2009) 1682-1687
9. Bisoendial R.J., Kastelein J.J., and Stroes E.S. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 195 (2007) e10-e18
10. Elliott P., Chambers J.C., Zhang W., et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302 (2009) 37-48
11. Casas J.P., Shah T., Cooper J., et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 35 (2006) 922-931
12. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
13. Ridker P.M., Danielson E., Fonseca F.A., et al., for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
14. Ridker P.M., Danielson E., Fonseca F.A., et al., on behalf of the JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373 (2009) 1175-1182